LIFE SAVING DRUGS PROGRAMME POST MARKET REVIEW

First Page		Document Content
Date: 2015-04-10 01:05:20 Medicine Pharmaceuticals policy Pharmacy Drug discovery Epidemiology Pharmaceutical Benefits Scheme Orphan drug Clinical trial Pharmaceutical industry Pharmaceutical sciences Pharmacology Health		LIFE SAVING DRUGS PROGRAMME POST MARKET REVIEW Add to Reading List Source URL: pbs.gov.au Download Document from Source Website File Size: 585,89 KB Share Document on Facebook

	The NIH Undiagnosed Diseases Program J A M E S P A N • 10 J U N E 2014 Stanford University School of Medicine In the United States, a rare disease defined by the 1983 Orphan Drug Act, is a disease that aﬀects fewer DocID: 1uQtE - View Document
	Development of new in silico methods to identify ligands for orphan GPCRs. Nathanael Weill and Didier Rognan. Bioinformatics of the Drug, UMR7175, Université Louis Pasteur Strasbourg, 74, route du Rhin, B.P.24 FI DocID: 1uh67 - View Document
	Edelman-DiagnosisDoesntHaveToBeRareLogoV3 DocID: 1rkUk - View Document
	Centre européen de biologie et de génomique structurales (CEBGS), unité 964 "Institut de génétique et de biologie moléculaire et cellulaire (IGBMC), Illkirch. DocID: 1r6Sz - View Document
	emea_strap_url_cmyk_rev_en_std_cent.eps MASTER DocID: 1qVx6 - View Document